Navigation Links
Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
Date:9/20/2007

SAN DIEGO, Sept. 20 /PRNewswire-FirstCall/ -- Sanofi-aventis, a licensee of Vical Incorporated (Nasdaq: VICL), announced on Monday the initiation of a 500-patient Phase 3 clinical trial of its NV1FGF angiogenesis therapy, which is based on Vical's non-viral DNA delivery technology. Assuming successful completion of the trial, called TAMARIS, sanofi-aventis expects to file for marketing approval in 2010.

The plasmid DNA (pDNA) therapy encodes Fibroblast Growth Factor 1 (FGF-1), a growth factor that stimulates the growth of blood vessels, and is intended to reduce the need for amputations in patients suffering from critical limb ischemia. Sanofi-aventis previously reported results from a Phase 2 trial in 107 patients demonstrating a statistically significant reduction in the rate of both major amputations and all amputations in patients receiving NV1FGF compared with those receiving placebo.

"In addition to DNA vaccines for infectious diseases and cancer, angiogenesis is among the most promising applications of our DNA delivery technology," said Vijay B. Samant, Vical's President and Chief Executive Officer. "The ability of pDNA to induce production of a protein locally at the site of injection ideally matches the desired treatment profile for critical limb ischemia, and perhaps for earlier stages of peripheral vascular disease. We are pleased that sanofi-aventis, one of our two partners in this field, has advanced into Phase 3 testing of this novel therapy addressing a major unmet medical need, and we look forward to successful completion of the trial."

The TAMARIS study is a double-blind, placebo-controlled Phase 3 trial in approximately 500 patients with critical limb ischemia. Four doses of 4 mg ea
'/>"/>

SOURCE Vical Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vaccine Can Prevent Cervical Cancer and Precancerous Lesions
2. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
3. Vical Licensee AnGes MG Announces Positive Results of Phase 3 Angiogenesis Trial in Japan
4. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
5. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
6. Vicals Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues
7. New England Journal of Medicine Publishes New Data on Gardasil, Mercks Cervical Cancer Vaccine
8. Cervarix, GSK Cervical Cancer Candidate Vaccine, Demonstrates 100 Percent Protection Against Precancerous Lesions Caused By Cancer-Causing Human Papillomavirus Types 16 & 18 for More Than Five Years
9. Vicals Vaxfectin Adjuvant Achieves Dose-Sparing Effect With Seasonal Influenza Vaccine
10. Nventa Announces Presentation of Positive HspE7 Data from NCI-Sponsored Clinical Trial in Cervical Dysplasia
11. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)...  Web Industries, Inc., a leading provider of ... Device, Advanced Composites, Consumer Products, and Wire & ... Specialties Preferred Converter by 3M,s Medical Specialties business ... streamline their supply chains by using Web as ... intermediate converting services, and contract manufacturing and assembly ...
(Date:3/3/2015)... 2015 Registration is officially open for MEDTEC China ... at the Shenzhen Convention & Exhibition Center. The ... to join the MEDTEC China family of events. MEDTEC China ... to better serve the South China ... an important region for China,s medical ...
(Date:3/3/2015)... Md. , March 3, 2015 /PRNewswire/-- ViaCyte, Inc., a ... islet replacement therapy for the treatment of diabetes in ... Eugene Brandon , Director of Strategic Relations and Project ... showcases the latest in type 1 diabetes management technology ... as follows: , , , Title:   , ...
Breaking Medicine Technology:Web Industries Receives 3M Preferred Converter Status 2Pre-registration Open for 2015 MEDTEC China South 2Pre-registration Open for 2015 MEDTEC China South 3ViaCyte to Present at JDRF TypeOneNation Research Summit 2
... MUNDELEIN, Ill., Sept. 10 Sysmex America, Inc. ... information systems developer, today announced that Laboratory Corporation ... ) has signed a five-year agreement for Sysmex ... for LabCorp,s primary testing laboratories.  Implementation of the ...
... ALTO, Calif., Sept. 10 Varian Medical Systems (NYSE: ... November 2 at the annual meeting of  the American Society ... and members of the financial community are invited to join ... a tour of the company,s exhibition at ASTRO. ...
Cached Medicine Technology:Sysmex America Announces LabCorp Hematology Automation Agreement 2Varian Medical Systems Schedules Investor Meeting and Fiscal Year End Review at ASTRO in San Diego, November 2, 2010 2
(Date:3/3/2015)... (PRWEB) March 03, 2015 NOVAtime ... of enterprise Time and Attendance / Workforce Management ... to NOVAtime SaaS Workforce Management / Time ... and attendance processes. , Since 2004, Innovative ... developmental disabilities with the best quality of life. ...
(Date:3/3/2015)... CA (PRWEB) March 03, 2015 Loma ... to whole health and well being, it will be ... machines across its campuses. , Over the past year, ... took part in creating dietary criteria, listening to vendors, ... for the entire organization. , Most recently, a ...
(Date:3/3/2015)... March 03, 2015 Findings could lead ... at UC Davis have developed and characterized a molecule ... causing them to self-destruct. This novel mechanism was found ... a usually fatal type of brain cancer – and ... , The article, to be published in the April ...
(Date:3/3/2015)... Dan E. Chambers, an experienced Los Angeles criminal ... recently spoke on the radio to give his insights into ... Independent Journal Review radio show “The Right Mics” chose Chambers ... and now as a criminal defense attorney would provide him ... and sentencing of this high-profile case. , During the ...
(Date:3/3/2015)... In March, 1% for the Planet , one ... new campaign, “Know Your Source,” which calls for consumers to ... their quest for ingredient awareness and better business practices. 1% ... and partners, including King Arthur Flour, Good Culture, Farm Aid, ... for food as an environmental issue, with a focus on ...
Breaking Medicine News(10 mins):Health News:Innovative Services, Inc. Successfully Migrates to Cloud-Based NOVAtime Workforce Management Solution to Support Growth and Improve Payroll Processing Time 2Health News:Innovative Services, Inc. Successfully Migrates to Cloud-Based NOVAtime Workforce Management Solution to Support Growth and Improve Payroll Processing Time 3Health News:Loma Linda University Health Rejuvenates Its Vending Machines with Healthier Selections 2Health News:News: UC Davis Scientists Describe Novel Drug Mechanism That Fights Brain Cancer 2Health News:News: UC Davis Scientists Describe Novel Drug Mechanism That Fights Brain Cancer 3Health News:News: UC Davis Scientists Describe Novel Drug Mechanism That Fights Brain Cancer 4Health News:Dan E. Chambers Gives Radio Interview Providing Insights into American Sniper Guilty Verdict 2Health News:Dan E. Chambers Gives Radio Interview Providing Insights into American Sniper Guilty Verdict 3Health News:1% For the Planet Asks Consumers to “Know Your Source” 2
... Brain health of aging African Americans and Hispanics will ... 6 at the Lincoln Theatre in,Washington, DC. Part ... research into the treatment of depression and stroke,prevention in ... present tips for successful aging. , WHEN: , Saturday, October 6, ...
... October is Breast Cancer Awareness,Month, and while ... at an,all-time high, the percentage of women receiving ... for Disease Control and,Prevention. Women should know that ... to maintain their long-term breast health. Listen ...
... Ill. - September 26, 2007 Research from ... capsule endoscopy diagnoses more Crohns disease recurrence after surgery ... for more than half of the patients studied. ... Endoscopy, the monthly peer-reviewed scientific journal of the American ...
... Capacity of the Nation,s Small Disadvantaged ... ... Congressional Black,Caucus Foundation (CBCF) and GlaxoSmithKline (NYSE: GSK ) today ... Corporate America assist small disadvantaged businesses (SDBs). Rep. Kendrick B. ...
... To Receive Outstanding Corporate Partnership Award from the Nevada ... ... The Nevada Immunization Coalitions,(NIC) today honored Anthem Blue Cross and ... Partnership Silver,Syringe Award. Anthem received this award as recognition for ...
... of California, San Diego (UCSD) School of Medicine have ... inflammation, cancer and cell injury act on cells to ... Joan Heller Brown, Ph.D., professor and chair of the ... mouse model that a newly discovered subtype of the ...
Cached Medicine News:Health News:Capsule endoscopy diagnoses more Crohn's disease recurrence after surgery than colonoscopy 2Health News:Capsule endoscopy diagnoses more Crohn's disease recurrence after surgery than colonoscopy 3Health News:Congressional Black Caucus Foundation and GlaxoSmithKline Announce Supplier Business Initiative Study Results 2Health News:Congressional Black Caucus Foundation and GlaxoSmithKline Announce Supplier Business Initiative Study Results 3Health News:Anthem Blue Cross and Blue Shield Partnership Plan Wins Nevada Immunization Award 2Health News:Enzyme's second messenger contributes to cell overgrowth 2
... Deluxe hinged knee brace provides ... all types of sports and ... contoured rubber pads to support ... patellar buttress and hyperextension stop. ...
... Knee Orthosis Custom-fitted static-progressive ... contractures. Goniometer version has ... exposed metal contacts skin. ... laundry bag. One size ...
... designed to treat children's injuries (ages 1 to ... compression to minimize hemarthrosis and swelling, and cold ... of the cuff, it can be utilized effectively ... patient. The Pediatric Ankle Cryo/Cuff is ideal for ...
... Unique in the Cryo/Cuff line, the ... cuff is filled directly with water and ... To ensure the optimal amount of compression, ... pressure after application. The cuff remains cold ...
Medicine Products: